SCHOOL OF MEDICINE

STANDARDIZED CURRICULUM VITAE FORMAT

Matthew C. Foster, MD

170 Manning Drive, CB# 7305

Chapel Hill, NC 27599-7305

(919) 966-6735 (fax)

Education

  • University of North Carolina School of Medicine, Division of Hematology/Oncology Fellowship Program

July 2006 to June 2009

Specialties: Hematology and Medical Oncology

  • University of North Carolina Hospitals, Department of Internal Medicine

June 2002 to June 2005

Specialty: Internal Medicine

  • M.D., University of North Carolina School of Medicine

May 2002

  • B.A. with Honors, University of North Carolina

May 1997

Major in Chemistry, Minor in German

  • Certifications and board eligibility:

Board certified in Hematology (2009)

Board certified in Medical Oncology (2009)

Board certified in Internal Medicine (2005)

Professional Experience -- Employment History

  • Clinical Assistant Professor (July 2009)

Leader, Inpatient Service Line NC Cancer Hospital (September 2014)

Clinical Director, Leukemia (December 2013)

Department of Medicine

Division of Hematology/Oncology

University of North Carolina School of Medicine

July 2009 to present

  • Clinical Assistant Professor

Department of Medicine

Division of General Internal Medicine

Section of Hospital Medicine

University of North Carolina School of Medicine

July 2005 to June 2006

  • Chemist I/II
    Research Triangle Institute
    Research Triangle Park, North Carolina

June 1997 to July 1998

Honors and Awards:

  • International Association for Comparative Research on Leukemia and Related Diseases Travel Award, 2009
  • ASCO/AACR Workshop: Methods in Clinical Cancer Research. Vail, CO, 2009
  • Chief Fellow, University of North Carolina School of Medicine, Department of Medicine, Division of Hematology/Oncology, 2009
  • David A. Ontjes Award, University of North Carolina Hospitals Internal Medicine Residency Program, 2003
  • Alpha Omega Alpha, elected September 2001
  • Merit Awards, University of North Carolina School of Medicine, 2000 and 2001
  • International Fellowship, University of North Carolina School of Medicine, 1999
  • Medical Alumni Loyalty Fund Scholarship, University of North Carolina School of Medicine, 1998 to 2002
  • Merck Index Award, University of North Carolina, Department of Chemistry, 1997
  • Phi Beta Kappa, University of North Carolina, elected 1996
  • University Honors Program, University of North Carolina, 1994-1997

Bibliography and products of scholarship

  • Books and chapters:
  • Foster MC. Successful eradication of factor VIII inhibitor in patient with mild Hemophilia A prior to hemipelvectomy for extensive

hemophilicpseudotumor. In: Ma A, Roberts H and Escobar M Eds. Hemophilia and Hemostasis, 2nd edition. Wiley-Blackwell, 2012.

  • Refereed papers/articles
  • Original Research:
  • Lim MY,Raval JS, Richards KL, Zeidner JF and Foster MC. Lenalidomide-associated hemolytic anemia. Leuk Lymphoma. 2015 Feb 3:1-8 [Epub ahead of print].
  • Foster MC, Amin C, Voorhees PM, Van Deventer HW, Richards, KL, Ivanova A, Whitman J, Chiu WM, Barr ND and Shea T. A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated GemtuzumabOzogamicin in Patients with Refractory or Relapsed Acute Myeloid Leukemia. Leuk Lymphoma. 2012 Jul;53(7):1331-7. Epub 2012 Jan 31. PMID: 22149206.
  • Other Peer Reviewed Articles
  • Montgomery ND, Dunphy CH, Mooberry M, Laramore A, Foster MC, Park SI and Fedoriw YD. Diagnostic Complexities of Eosinophilia. Arch Pathol Lab Med. 2013 Feb; 137(2):259-69. PMID: 23368869.
  • Buckner TW, Dunphy CH, Fedoriw YD, van Deventer HW, Foster MC, Richards KL and Park SI. Complete Spontaneous Remission of Diffuse Large B-Cell Lymphoma of the Maxillary Sinus After Concurrent Infections. Clin Lymphoma, Myeloma Leuk. 2012 Dec; 12(6):455-8. PMID: 23025990.
  • Foster MC, Gabriel DA, Shea TC. The Role of hematopoietic stem cell transplantation in the management of follicular lymphoma. The Oncologist, 2009;14:726-738. PMID: 19561292. PMCID: PMC2948435.
  • Published abstracts
  • Stock W, Luger SM, Advani AS, Geyer S, Harvey RC, Mullighan CG, Willman CL, Malnassy G, Parker E, Laumann KM, Sanford B, Marcucci G, Paietta EM, Liedtke M, Claxton DF, Foster MC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM and Larson RA. Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. Blood (ASH Annual Meeting Abstracts), Dec 2014; 124(21):796.
  • Park SI, Richards KL, Olajide O, Reddy NM, Ghosh N, Budde EE, Foster MC, Deal AM, Noe JF, Shea TC and Ansell SM. A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By BrentuximabVedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts), Dec 2014; 124(21):4431.
  • Zeidner JF, Foster MC, Blackford A, Litzow MR, Morris L, Strickland SA, Lancet JE, Bose P, Levy Y, Tibes R, Gojo I, Gocke CD, Rosner GL, Greer J, Cain JM, Little RF, Wright JJ, Doyle LA, Smith BD and Karp JE. Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML). J ClinOncol (2014 ASCO Annual Meeting Abstracts) 32:5s, 2014 (suppl; abstr 7002).
  • Priola GM, Deal AM, Richardson BM, Foster MW, Thompson JW, Moseley MA, Foster MC and Blatt J. Cerebrospinal Fluid Correlates of L-Asparaginase-Related Thrombotic Events. Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 3876.
  • Sanford B, Luger S, Devidas M, Larsen EC, Liedtke M, Voorhees PM, Foster MC, Claxton DF, Geyer S, Parker E, Coffan K, Carroll WL, Winick NJ, Coutre, SE, Tallman MS, Appelbaum FR, Erba HP, Stone RM, Hunger SP, Larson RA and Stock W. Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 3903.
  • Park SI, Richards KL, Asch AS, Olajide O, Deal AM, Ivanova A, Wall JG, Sobol AL, Foster MC, Muss HB and Shea TC. A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts), Oct 2013; 122: 1791.
  • Foster MC, Park SI, Moore D, Dodd A, Barr A and Shea TC. Heterogeneity of Adult Acute Lymphoblastic Leukemia Among Racial and Ethnic Minorities in a Diverse Single-Institution Population: Inferior Progression-Free Survival Among Hispanics and Patients Not Completing Maintenance Chemotherapy. Blood (ASH Annual Meeting Abstracts), Nov2012; 120: 4291.
  • Muffly LS, Stock W, Breitenbach K, Mulkey F, Luger S, Advani A, Parker E, Foster MC, Liedtke M, Garcia R, Coffan K, Sipin-Sayno J, McNeer J, Tallman MS, Appelbaum FR, Stone RM and Larson RA. Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 3535.
  • Zeidner JF, Gerber JM, Blackford A, Litzow M, Foster MC, Morris LE, Gojo I, Lancet JE, Bose P, Tibes R, Strickland SA, Greer JM, Drye M, Meads K, Doyle A, Little RF, Wright JJ and Karp JE. Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 47.
  • Dean A, Hayden M, Rao KW, Fedoriw YD, Qaquish B and Foster MC. Isolated Chromosome 20q Deletions in Patients with Non-Myeloid Disorders. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1442.
  • Lancet JE, Feldman E, Foster MC, Gojo I, Olatoyosi O, Komrokji RS, Strair R, Kaufmann SH, Knoblauch R, Karkera

JD, Wright JJ and Karp JE. Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously

Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1508.

  • Foster MC, Walko CM, Kumar P, Huang J, Ivanova A, Van Deventer H and Shea TS. Impairment of clofarabine (CLO) clearance (CL) in the presence of cimetidine: Evidence of a drug-drug interaction between clofarabine and inhibitors of human organic cation transporter-2 (hOCT2).In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar31-Apr4; Chicago, IL. Philadelphia(PA): AACR; 2012. Abstract nr 750.
  • Rojas Balcazar JM, Fedoriw Y, Foster M, Maguire J and Ford HJ. Pulmonary Arterial Hypertension in the Setting of Recurrent Pleural Effusion Due to ExtramedullaryHematopoeisis. In: Proceedings of the American Thoracic Society 2011 International Conference: Am J RespirCrit Care Med 183;2011:A1933.
  • Foster MC, Amin C, Voorhees PM, Van Deventer HW, Richards KL, Ivanova A, Whitman J, Shea TC. A phase I, dose escalation study of clofarabine in combination with fractionated gemtuzumabozogamicin in relapsed and refractory acute myeloid leukemia (AML). Blood, 51st ASH Annual Meeting Abstracts. 2009. Abstract 2048, pg. 808-809.
  • Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Dodd A, Foster MC, Gabriel DA, Shea TC, Serody J, Van Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study. Blood, 51st ASH Annual Meeting Abstracts. 2009. Abstract 306, pg. 129-130.
  • Foster MC, Christensen R, Egan J, Whitley J, Chiu M, Serody J, Gabriel D, Ivanova A, Dunphy CH, Shea TC. Prognostic impact of bone marrow CD138 immunohistochemistry (IHC) prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM). J ClinOncol, ASCO Annual Meeting Abstracts, 2009. Vol 27, No 15s. Abstract 8600, pg. 458s.
  • Seltzman HH, Foster MC, Wyrick CD, Burgess JP and Carroll FI. Tritium Labeling of the Peripheral Cannabinoid Receptor Ligand SR144528.Drug and Alcohol Dependence vol. 63, pg. S142, 2001.
  • Seltzman HH, Foster MC, Wyrick CD and Carrol FI. Synthesis of Tritium Labelled SR144528 by Metallation and

Tri-n-ButyltinTritide Quenching. NIDA Research Monograph, Problems of Drug Dependence, Proceedings of the 60 th Annual Scientific Meeting vol. 179, pg. 249, 1999.

  • Seltzman HH, Foster MC, Wyrick CD, Gilliam AF, Thomas BF, Carroll FI. Tritium Labeling of the Cannabinoid CB2 Receptor Antagonist SR144528 and its Receptor Binding. International Cannabinoid Research Society Abstracts pg. 85, July 1998.
  • Stone WL, Papas AM, LeClair IO, Neumann A and Foster M. The Roles of Alpha- and Gamma-Tocopherols in Preventing the Formation of Fecal Mutagens. FASEB Journal Abstracts Vol 9, Part 1, #3, A472, Abstract 2736, 1995.
  • In Press/Submitted:
  • Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD and Karp JE. Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) vs. cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia (AML)" submitted, Haematologica.
  • Zeidner JF and Foster MC, Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML). In press, Current Drug Targets.
  • Refereed Other Products of Scholarship
  • Lim MY and Foster MC. Keys to Diagnosing Common Toxicities In: Harris JE ed. Medscape Reference. WebMD LLC, 2013:
  • Foster MC. Myelodysplastic Syndromes Treatment Protocols. In: Harris JE ed. Medscape Reference. WebMD LLC, 2011:
  • Foster MC.Myelodysplastic Syndromes Staging. In: Harris JE ed. Medscape Reference. WebMD LLC, 2011:

Teaching activities

  • Lectures:
  • Fellows didactic lecture, UNC Division of Hematology/Oncology: Acute Leukemia. Annually 2009-present.
  • Oncology Core Lecture, UNC Hospital, Chapel Hill, NC: Bone Marrow Failures Syndromes, September 12, 2014.
  • Attending on Clinical Service:
  • Attending on inpatient clinical hematologic malignancies service – 1 month per year, 2009-present.
  • Supervision:
  • Primary supervising physician for:
  • Laura Blanchard, PA – April 2014-present
  • Melissa Matson, NP – August 2014-present
  • Sean Gallagher, NP – August 2014-present
  • Katherine Pepin, NP – January 2015-present
  • Jon Ptachcinski, PharmD – October 2014-present
  • Lucas S. Wind, PharmD – December 2014-present

Grants

Active:

  • Principal Investigator, RV-AML-PI-0687 (Celgene Corporation): An Open-Label Dose-Finding Study of Lenalidomide as Consolidation Followed by Lenalidomide Maintenance Therapy for Adults >/= 60 Years of Age with AML in Partial or Complete Response Following Conventional Induction Therapy; 6/2012 to present.

Completed:

  • Awardee, UNC Oncology Clinical Translational Research Training Program NIH K12CA120780; 7/2010 to 6/2012; PI: Richard Goldberg, M
  • Principal Investigator, iCLO134 (Genzyme), A Pharmacokinetic Study Of Oral And Intravenous Clofarabine In Patients With High Risk Myelodysplasia And Acute Leukemias—Determination Of Oral Bioavailability And The Effect Of Cimetidine On Clofarabine Clearance, 9/2010 to 7/2012.
  • Trainee, University of North Carolina Hematology NIH T32 HL007149-31 Training Grant 7/2007 to 6/2009; PI: Nigel Key, MD

1

Revised 9/2014